CYP19A1 and breast cancer: Recently, Turnbull et al. had developed a model in the identification of the biomarkers specific to letrozole, an aromatase inhibitor, among breast cancer patients [49], thereby contributing to the further identification of drug-specific biomarkers for the development of personalized cancer therapies.